Mannatech (MTEX) Competitors $9.57 +0.30 (+3.24%) Closing price 04:00 PM EasternExtended Trading$9.30 -0.28 (-2.87%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. QNTM, INKT, CMMB, COEP, ADVM, MNOV, CUE, GNTA, ALGS, and KALAShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Quantum Biopharma (QNTM), MiNK Therapeutics (INKT), Chemomab Therapeutics (CMMB), Coeptis Therapeutics (COEP), Adverum Biotechnologies (ADVM), MediciNova (MNOV), Cue Biopharma (CUE), Genenta Science (GNTA), Aligos Therapeutics (ALGS), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors Quantum Biopharma MiNK Therapeutics Chemomab Therapeutics Coeptis Therapeutics Adverum Biotechnologies MediciNova Cue Biopharma Genenta Science Aligos Therapeutics KALA BIO Mannatech (NASDAQ:MTEX) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Which has preferable earnings & valuation, MTEX or QNTM? Mannatech has higher revenue and earnings than Quantum Biopharma. Mannatech is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.15$2.49M-$2.04-4.69Quantum BiopharmaN/AN/A-$14.20M-$14.02-1.00 Does the media refer more to MTEX or QNTM? In the previous week, Mannatech had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 2 mentions for Mannatech and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 1.11 beat Mannatech's score of -0.50 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Quantum Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MTEX or QNTM? 13.0% of Mannatech shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, MTEX or QNTM? Mannatech has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Is MTEX or QNTM more profitable? Quantum Biopharma has a net margin of 0.00% compared to Mannatech's net margin of -3.46%. Mannatech's return on equity of -48.60% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-3.46% -48.60% -10.70% Quantum Biopharma N/A -270.22%-131.87% SummaryMannatech beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.18M$2.64B$5.77B$9.93BDividend YieldN/A49.35%6.67%4.52%P/E Ratio-4.6923.0375.6026.68Price / Sales0.15752.40555.18213.69Price / Cash4.43169.7737.1158.92Price / Book2.095.5011.446.09Net Income$2.49M$32.95M$3.28B$266.14M7 Day Performance3.92%2.69%0.84%0.27%1 Month Performance19.77%7.87%7.15%4.13%1 Year Performance27.26%0.79%59.65%23.93% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech0.4347 of 5 stars$9.57+3.2%N/A+21.0%$18.18M$117.87M-4.69250Short Interest ↑Gap UpQNTMQuantum BiopharmaN/A$17.28-2.5%N/AN/A$66.95MN/A-1.23N/APositive NewsGap UpINKTMiNK Therapeutics1.7865 of 5 stars$14.76+1.3%$37.50+154.2%+72.0%$66.69MN/A-5.1230Positive NewsShort Interest ↑CMMBChemomab Therapeutics3.3439 of 5 stars$3.50+0.4%$8.50+143.2%-68.5%$65.92MN/A-5.9220News CoverageShort Interest ↓COEPCoeptis Therapeutics1.476 of 5 stars$13.63-0.2%N/A+203.2%$65.70MN/A-2.352Short Interest ↓Gap UpADVMAdverum Biotechnologies3.2953 of 5 stars$3.14+3.8%$19.75+528.2%-53.2%$65.67M$1M-0.40190MNOVMediciNova1.9404 of 5 stars$1.36+2.7%$7.00+416.6%-24.0%$64.37M$1M-5.4210CUECue Biopharma1.3329 of 5 stars$0.83+1.7%N/A+18.8%$63.94M$9.29M-1.4960GNTAGenenta Science2.7607 of 5 stars$3.50+0.1%$25.00+615.3%-13.6%$63.92MN/A0.007Gap UpALGSAligos Therapeutics4.2859 of 5 stars$10.29+0.7%$50.00+386.1%-8.5%$63.26M$3.17M-0.5290KALAKALA BIO2.8394 of 5 stars$8.98+2.2%$13.00+44.8%+141.4%$62.90M$3.89M-1.3230Trending NewsAnalyst UpgradeAnalyst RevisionGap Down Related Companies and Tools Related Companies QNTM Alternatives INKT Alternatives CMMB Alternatives COEP Alternatives ADVM Alternatives MNOV Alternatives CUE Alternatives GNTA Alternatives ALGS Alternatives KALA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTEX Stock Alerts